World Health Organization Prequalification Programme / Janssen-Cilag International NV, 2019-04: WHO's public assessment report for the prequalified 500 mg chewable Vermox states the indication for mass treatment of soil-transmitted helminths in everyone aged one year and over, and records the Portuguese contract manufacturer. It is the public regulatory dossier behind UN procurement of the product.
Vermox Chewable, manufactured at Lusomedicamenta Sociedade Tecnica Farmaceutica S.A.; Barcarena, Portugal was included in the WHO list of prequalified medicinal products for large scale preventive chemotherapy interventions for the control of soil-transmitted helminth infections on 5 April 2019.
p. 1
World Health Organization Prequalification Programme / Janssen-Cilag International NV, 2019-04: WHO's public assessment report for the prequalified 500 mg chewable Vermox states the indication for mass treatment of soil-transmitted helminths in everyone aged one year and over, and records the Portuguese contract manufacturer. It is the public regulatory dossier behind UN procurement of the product. WHO regulatory assessment document. Related WHOPAR part 7 (https://extranet.who.int/prequal/sites/default/files/whopar_files/NT006part7v1.pdf) records that 'The company Janssen-Cilag submitted in 2018 an application for VERMOX CHEWABLE (NT006)' and that licensing status is 'licensed / registered in the United States of America'. No trial data of its own; efficacy and safety accepted on published literature and WHO preventive-chemotherapy experience. Study type: regulatory record.
